For approximately 98% of non-diabetic individuals with obesity and mild metabolic syndrome, semaglutide (GLP-1) is the most potent medication needed; more powerful GLP-1/GIP combination agonists (like tirzepatide/Mounjaro) and triple agonists are unnecessary and create an 'arms race' of escalation driven by pharmaceutical competition rather than clinical need.